drugset / Trial / NCT02259790

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

NCT02259790

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative bioavailability of fixed-dose combination tablet vs. mono-components of telmisartan and amlodipine

Timeline

Start
2007-07
Primary completion
2007-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Telmisartan Other / unclassified 40 mg Oral

Indications

No indication recorded.